November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways
Sep 22, 2025, 06:33

Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways

 

Dr. Mukesh, Assistant Professor of Clinical Immunology and Rheumatology at King George’s Medical University (KGMU), posted on X:

”Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways

  •  APS affects 0.5% of the population but is a major cause of recurrent pregnancy loss (RPL), preeclampsia and FGR.
  • Pathogenesis: “Two-hit model” → aPL antibodies trigger endothelial/placental dysfunction → thrombosis + insufficiency.
  • Lupus anticoagulant (LA) = strongest predictor of poor outcomes.
  • Standard of care: Low-dose aspirin (LDA) + LMWH → boosts live birth rates.
  • Hydroxychloroquine (HCQ) reduces preterm birth and improves placental health in high-risk cases.
  • Refractory APS? → Novel options: TNF-α inhibitors, complement blockers (eculizumab), nitric oxide modulators, statins.
  • APS + SLE overlap = compounded risks → needs aggressive, multidisciplinary management.
  • CAPS (catastrophic APS) = rare but lethal; pregnancy can trigger it (mortality ~36%).
  • New 2023 ACR/EULAR criteria improve APS classification and risk stratification in pregnancy.

Bottom line: Early diagnosis, tailored therapy, and multidisciplinary care = better outcomes for mom and baby.”

Read the full review here.

Title: Antiphospholipid syndrome in pregnancy: a comprehensive literature review

Authors: Viorela Romina Murvai, Radu Galiș, Anca Panaitescu, Casandra Maria Radu, Timea Claudia Ghitea, Paula Trif, Miruna Onița-Avram, Alexandra Alina Vesa, Anca Huniadi

Antiphospholipid Syndrome (APS) in Pregnancy - Key Takeaways

Stay updated with Hemostasis Today.